KR20210086606A - 원자 양자 클러스터의 치료적 용도 - Google Patents

원자 양자 클러스터의 치료적 용도 Download PDF

Info

Publication number
KR20210086606A
KR20210086606A KR1020217008140A KR20217008140A KR20210086606A KR 20210086606 A KR20210086606 A KR 20210086606A KR 1020217008140 A KR1020217008140 A KR 1020217008140A KR 20217008140 A KR20217008140 A KR 20217008140A KR 20210086606 A KR20210086606 A KR 20210086606A
Authority
KR
South Korea
Prior art keywords
composition
aqc
cancer
cells
metal atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217008140A
Other languages
English (en)
Korean (ko)
Inventor
페르난데즈 데이비드 부체타
페르난도 도밍게스 푸엔테
퀸텔라 마누엘 아르투로 로페즈
Original Assignee
나노갭 서브-엔엠-파우더, 쏘시에다드 아노니마
유니버시다데 데 산티아고 데 콤포스텔라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나노갭 서브-엔엠-파우더, 쏘시에다드 아노니마, 유니버시다데 데 산티아고 데 콤포스텔라 filed Critical 나노갭 서브-엔엠-파우더, 쏘시에다드 아노니마
Publication of KR20210086606A publication Critical patent/KR20210086606A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C5/00—Alloys based on noble metals
    • C22C5/06—Alloys based on silver
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/12—Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/20—Electrolytic production, recovery or refining of metals by electrolysis of solutions of noble metals
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C5/00—Electrolytic production, recovery or refining of metal powders or porous metal masses
    • C25C5/02—Electrolytic production, recovery or refining of metal powders or porous metal masses from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2202/00—Treatment under specific physical conditions
    • B22F2202/11—Use of irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Nanotechnology (AREA)
  • Electrochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217008140A 2018-09-26 2019-09-25 원자 양자 클러스터의 치료적 용도 Ceased KR20210086606A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18196959 2018-09-26
EP18196963 2018-09-26
EP18196959.3 2018-09-26
EP18196963.5 2018-09-26
PCT/ES2019/070637 WO2020065115A2 (es) 2018-09-26 2019-09-25 Usos terapéuticos de clústeres cuánticos atómicos

Publications (1)

Publication Number Publication Date
KR20210086606A true KR20210086606A (ko) 2021-07-08

Family

ID=68342935

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217008140A Ceased KR20210086606A (ko) 2018-09-26 2019-09-25 원자 양자 클러스터의 치료적 용도

Country Status (11)

Country Link
US (1) US20220031740A1 (https=)
EP (1) EP3862109A2 (https=)
JP (2) JP2022502450A (https=)
KR (1) KR20210086606A (https=)
CN (2) CN113179632A (https=)
AU (2) AU2019349780B2 (https=)
BR (1) BR112021005775A2 (https=)
CA (1) CA3111915A1 (https=)
IL (1) IL281663A (https=)
MX (1) MX2021003566A (https=)
WO (1) WO2020065115A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303421C (zh) * 2004-03-24 2007-03-07 南京大学 一种用于有机氯、有机磷农药分析的同步净化提取方法
KR102927722B1 (ko) * 2020-05-09 2026-02-19 선전 프로파운드 뷰 파마슈티칼 테크놀로지 컴퍼니 리미티드 비정형 항정신병약물에 의해 유발되는 부작용의 치료
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277531B2 (es) * 2005-08-03 2008-07-16 Universidad De Santiago De Compostela Procedimiento para la obtencion de clusteres cuanticos atomicos.
CN101113046A (zh) * 2006-07-25 2008-01-30 安正五 纳米胶体银水的制备方法
ES2319064B1 (es) * 2007-10-05 2010-02-15 Universidad De Santiago De Compostela Uso de clusteres cuanticos atomicos (aqcs) como antimicrobianos y biocidas.
CN101486733B (zh) * 2009-03-09 2011-05-25 华南师范大学 含氧桥双核钼原子簇化合物及其制备方法和用途
EP2457572A1 (en) * 2010-11-05 2012-05-30 Universidade De Santiago De Compostela Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases
WO2015015301A2 (en) * 2013-07-31 2015-02-05 Palama Ilaria El Cancer therapy with silver nanoparticles
KR20210021306A (ko) * 2018-06-12 2021-02-25 나노갭 서브-엔엠-파우더, 쏘시에다드 아노니마 정제된 원자 양자 클러스터를 제조하는 방법

Also Published As

Publication number Publication date
MX2021003566A (es) 2021-08-16
AU2025238114A1 (en) 2025-10-23
WO2020065115A2 (es) 2020-04-02
BR112021005775A2 (pt) 2021-06-29
EP3862109A2 (en) 2021-08-11
CN113179632A (zh) 2021-07-27
AU2019349780A1 (en) 2021-03-25
WO2020065115A3 (es) 2020-05-22
US20220031740A1 (en) 2022-02-03
AU2019349780B2 (en) 2025-07-03
CA3111915A1 (en) 2020-04-02
JP2022502450A (ja) 2022-01-11
JP2024122998A (ja) 2024-09-10
CN120053481A (zh) 2025-05-30
IL281663A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
Gamberi et al. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness
JP2024122998A (ja) 原子量子クラスターの治療的使用
EP3328375B1 (en) Methods for cancer and immunotherapy using glutamine analogues, including don
EP2673250B1 (en) Stilbene analogs and methods of treating cancer
CN105658809B (zh) 肿瘤选择性联合疗法
EP1677740A2 (en) Methods and compositions for treating cancer
Ohman et al. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic
US20060078494A1 (en) Use of inhibitors of 24-hydroxylase in the treatment of cancer
KR20180086257A (ko) 환자에서 전이 암의 효과적인 치료를 위한 병용요법
CN102014891A (zh) 增加癌症患者存活时间的化合物的组合物和使用方法
CN113453690A (zh) 用于抗衰老的三联疗法
HK40057518A (en) Therapeutic uses of atomic quantum clusters
Wang et al. Repurposing antihistamine to chemotherapy via a molecular delivery platform co-targeting mitochondria and endoplasmic reticulum
EP3871665B1 (en) Inhibitors of rna-binding proteins as anti-cancer drugs
EP4541425A2 (en) Treating cancers with combinations of acylfulvenes with ibrutinib or bortezomib
US20240009212A1 (en) Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof
JP2025533472A (ja) 原子量子クラスター誘導体を生成するための方法
ES2897790T3 (es) Un agente que aumenta la expresión del agonista asociado a Bcl2 de la muerte celular para el tratamiento del cáncer
Chen et al. Glucose Limitation Sensitizes Cancer Cells to Selenite-Induced Cytotoxic Effect via SLC7A11-Mediated Redox Collapse
WO2026036187A1 (en) Methods of treating cns cancers
ES2930009T3 (es) Métodos para el cáncer e inmunoterapia con análogos de glutamina, comprendiendo deoxinivalenol DON incluido
ES2613031T3 (es) Compuestos antiproliferativos y su utilización
Tan Autophagy as a Survival Mechanism for Tumor Cells Exposed to Chemotherapy or Hypoxia, and its Inhibition by Pantoprazole to Improve Outcome of Treatment
JP2020075894A (ja) 抗血液悪性腫瘍薬
Millard Discovery of novel small molecules targeting cancer cell metabolism

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000